相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Identification of chemoresistance-related mRNAs based on gemcitabine-resistant pancreatic cancer cell lines
Jiarong Zhou et al.
CANCER MEDICINE (2020)
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs
Tejaswini P. Reddy et al.
BREAST CANCER RESEARCH (2020)
An auristatin-based antibody-drug conjugate targeting HER3 enhances the radiation response in pancreatic cancer
Laura Bourillon et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer
Aida Sampera et al.
MOLECULAR CANCER THERAPEUTICS (2019)
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
T. Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Chemoresistance and the Self-Maintaining Tumor Microenvironment
Gulcen Yeldag et al.
CANCERS (2018)
An oligoclonal antibody durably overcomes resistance of lung cancer to third-generation EGFR inhibitors
Maicol Mancini et al.
EMBO MOLECULAR MEDICINE (2018)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+Breast Cancers With ERBB Ligand Overexpression
Luis J. Schwarz et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Pan-HERAn antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers
Sofie Ellebaek et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Nikolaos Ioanou et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2016)
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mari Iida et al.
MOLECULAR CANCER THERAPEUTICS (2016)
MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations
Sabrina Arena et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
Establishment and characterization of gemcitabine-resistant human cholangiocarcinoma cell lines with multidrug resistance and enhanced invasiveness
Wareeporn Wattanawongdon et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2015)
In vivo imaging of therapy response to a novel Pan-HER antibody mixture using FDG and FLT positron emission tomography
Carsten H. Nielsen et al.
Oncotarget (2015)
Four-in-One Antibodies Have Superior Cancer Inhibitory Activity against EGFR, HER2, HER3, and VEGF through Disruption of HER/MET Crosstalk
Shi Hu et al.
CANCER RESEARCH (2015)
Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States
Lola Rahib et al.
CANCER RESEARCH (2014)
MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Jonathan B. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse
Stanislas du Manoir et al.
MOLECULAR ONCOLOGY (2014)
HER3 as biomarker and therapeutic target in pancreatic cancer: new insights in pertuzumab therapy in preclinical models
Gaeelle Thomas et al.
ONCOTARGET (2014)
Activation of HER3 Interferes with Antitumor Effects of Axl Receptor Tyrosine Kinase Inhibitors: Suggestion of Combination Therapy
Robert Torka et al.
NEOPLASIA (2014)
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett et al.
CLINICAL CANCER RESEARCH (2013)
Therapeutic Advances in Pancreatic Cancer
Andrew Scott Paulson et al.
GASTROENTEROLOGY (2013)
Impact of FOLFIRINOX Compared With Gemcitabine on Quality of Life in Patients With Metastatic Pancreatic Cancer: Results From the PRODIGE 4/ACCORD 11 Randomized Trial
Sophie Gourgou-Bourgade et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
C. Hage et al.
CELL DEATH & DISEASE (2013)
Anti-HER3 Domain 1 and 3 Antibodies Reduce Tumor Growth by Hindering HER2/HER3 Dimerization and AKT-Induced MDM2, XIAP, and Fox01 Phosphorylation
Yassamine Lazrek et al.
NEOPLASIA (2013)
Mechanisms of chemoresistance in cancer stem cells
Lissa Nurrul Abdullah et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2013)
Cancer drug resistance: an evolving paradigm
Caitriona Holohan et al.
NATURE REVIEWS CANCER (2013)
Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors
Timothy R. Wilson et al.
NATURE (2012)
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts
C. Larbouret et al.
ANNALS OF ONCOLOGY (2010)
ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma
J. Spencer Liles et al.
CANCER BIOLOGY & THERAPY (2010)
MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth
Yu-Wen Zhang et al.
CANCER RESEARCH (2010)
Roles for Growth Factors in Cancer Progression
Esther Witsch et al.
PHYSIOLOGY (2010)
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Thiruvengadam Arumugam et al.
CANCER RESEARCH (2009)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
In vivo therapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas
Christel Larbouret et al.
CLINICAL CANCER RESEARCH (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma
H Safran et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2001)
The protein tyrosine kinase family of the human genome
DR Robinson et al.
ONCOGENE (2000)
分享论文
